Translational & Precision Medicine (TPM) Network

Network Goals

Scientific Expertise:

The Translational & Precision Medicine (TPM) Network and associated Communities facilitate interactions among experts across multidisciplinary fields to foster translational science with a focus on individuals via patient care and society via healthcare. The interactions are through social media, email blasts, and teleconferences with focused scientific content.

Catalyst for Innovation:

The TPM Network is a catalyst for innovation by sponsoring a range of scientific programs at the Annual Meeting focused on translational and precision medicine.

Influence and Impact:

The TPM Network is the lead group engaged in translational and precision medicine and optimal pharmacotherapy in patient care.

Education and Communication:

The TPM Network offers educational opportunities via the Communities.

Organizational Effectiveness:

Leadership within TPM is expanded by a Network Steering Committee.
The TPM Network has regularly scheduled teleconferences and utilizes social media to engage members throughout the year.
The TPM Network fosters the career of its members by assisting Communities in recognizing members for individual achievements and contributions to ASCPT, sponsoring educational programming in translational and precision medicine, and providing opportunities for networking activities throughout an individual’s career.

ASCPT Members-Only Webinar Presented by the Oncology (ONC) and Pharmacometrics & Pharmacokinetics (PMK) Communities
Title: A Semi-Mechanistic PK/PD Model to Project Undetectable Minimal Residual Disease Rates in Chronic Lymphocytic Leukemia Studies
Date and Time: Tuesday, May 11, 2021, 12:00 pm EST
Speakers: Sathej Gopalakrishnan, PhD, and Ahmed H. Salem, PhD
Moderators: Deanna Brackman, PhD, and Neeraj Gupta, PhD
Description: Understanding the kinetics of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is an important aspect during the development of fixed duration targeted therapies. This webinar will introduce the clinical implications of MRD for the treatment of CLL and will include broader discussions on both MRD as an endpoint in hematological malignancies as well as the PK/PD modeling concepts utilized.

Additionally, the presenters will speak about the objective to develop, qualify, and utilize a semi-mechanistic PK/PD model to evaluate the impact of venetoclax-rituximab combination therapy on the kinetics of MRD in CLL patients. Such fit-for-purpose models have great potential in assisting clinical development of targeted therapies in hematologic oncology. Attend the session to learn more about the development of the model and how the findings and concepts provide the framework for applying similar models to drug development in all hematological malignancies and would provide substantial impact, especially on the topic of predicting sustained response that may allow for fixed duration therapies.
Register Now!